Royal Bank of Canada Lowers Korro Bio Target Price to $95, Potential Upside of 293.78%

Summary

Royal Bank of Canada has lowered Korro Bio’s (NASDAQ: KRRO) target price from $105.00 to $95.00, while maintaining an ‘outperform’ rating. This indicates a potential upside of 293.78% from the current price of $24.13. Other analysts also provide positive ratings, with an average target price of $142.57. Korro Bio’s stock has recently decreased by 0.2%, and institutional investors are actively adjusting their holdings in the company.Market Beat

Impact Analysis

The event is classified at the company level as it specifically concerns Korro Bio’s stock target price adjustment. The downgrade in target price by the Royal Bank of Canada suggests a more cautious outlook on the stock’s potential, although they still see significant upside. The consensus among analysts remains positive, with a substantial average target price, indicating continued investor confidence in the company. The slight recent decline in stock price may reflect market reactions to the revised target, while institutional investor movements could further influence volatility. Investors should consider the potential risks and rewards, focusing on the large expected upside and the prevailing ‘buy’ ratings from analysts.Market Beat